Drugs / CD19/BCMA CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07324889 | Jan 2026 → Oct 2027 expected | autoimmune hemolytic anemia, warm type | Yihao Wang | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19/BCMA CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07324889 ↗ |
| Modality | Cell therapy | “CD19/BCMA CAR-T Cell Therapy” NCT07324889 ↗ |
| Target | CD19 | “CD19/BCMA CAR-T Cell Therapy” NCT07324889 ↗ |